These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 3877878)

  • 1. Bromocriptine potentiates the behavioural effects of directly and indirectly acting dopamine receptor agonists in mice.
    Jenkins OF; Jackson DM
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Oct; 331(1):7-11. PubMed ID: 3877878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypothesis: bromocriptine lacks intrinsic dopamine receptor stimulating properties.
    Jackson DM; Jenkins OF
    J Neural Transm; 1985; 62(3-4):219-30. PubMed ID: 3897455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further studies on the interaction between bromocriptine and SKF38393 in reserpine and alpha methyl-para-tyrosine-treated mice.
    Jackson DM; Ross SB; Hashizume M
    Psychopharmacology (Berl); 1988; 94(3):321-7. PubMed ID: 2895938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromocriptine induces climbing behaviour: possible D-1 or D-2 dopamine receptor involvement.
    Zarrindast MR; Shahed-Dirin K
    Psychopharmacology (Berl); 1990; 100(2):275-80. PubMed ID: 2305016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mode of action of bromocriptine following pretreatment with reserpine and alpha-methyl-p-tyrosine in rats.
    Ushijima I; Mizuki Y; Yamada M
    Psychopharmacology (Berl); 1988; 95(1):29-33. PubMed ID: 2898789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relative importance of dopamine and noradrenaline receptor stimulation for the restoration of motor activity in reserpine or alpha-methyl-p-tyrosine pre-treated mice.
    Dolphin AC; Jenner P; Marsden CD
    Pharmacol Biochem Behav; 1976 Jun; 4(6):661-70. PubMed ID: 981283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of dopamine receptor agonist treatment on haloperidol-induced supersensitivity in mice.
    Fayle P; Jackson DM; Jenkins OF; Lafferty PA
    Pharmacol Biochem Behav; 1985 Nov; 23(5):715-20. PubMed ID: 4080755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions between endogenous dopamine and dopamine agonists at release modulatory receptors: multiple effects of neuronal uptake inhibitors on transmitter release.
    Hoffmann IS; Talmaciu RK; Cubeddu LX
    J Pharmacol Exp Ther; 1986 Aug; 238(2):437-46. PubMed ID: 2942676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bromocriptine induces marked locomotor stimulation in dopamine-depleted mice when D-1 dopamine receptors are stimulated with SKF38393.
    Jackson DM; Hashizume M
    Psychopharmacology (Berl); 1986; 90(1):147-9. PubMed ID: 3094056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolite involvement in bromocriptine-induced circling behaviour in rodents.
    Reavill C; Jenner P; Marsden CD
    J Pharm Pharmacol; 1980 Apr; 32(4):278-84. PubMed ID: 6103058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement by a single dose of reserpine (plus alpha methyl-p-tyrosine) of the central stimulatory effects evoked by dopamine D-1 and D-2 agonists in the mouse.
    Ross SB; Jackson DM; Wallis EM; Edwards SR
    Naunyn Schmiedebergs Arch Pharmacol; 1988 May; 337(5):512-8. PubMed ID: 3261844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic and persistent interaction between the D2 agonist, bromocriptine, and the D1 selective agonist, CY 208-243.
    Robertson HA; Peterson MR; Worth GG
    Brain Res; 1992 Oct; 593(2):332-4. PubMed ID: 1360321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.
    Johnson AM; Loew DM; Vigouret JM
    Br J Pharmacol; 1976 Jan; 56(1):59-68. PubMed ID: 943193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioural, biochemical and electrophysiological studies on the motor depressant and stimulant effects of bromocriptine.
    Jackson DM; Martin LP; Larsson LG; Cox RF; Waszczak BL; Ross SB
    Naunyn Schmiedebergs Arch Pharmacol; 1990 Sep; 342(3):290-9. PubMed ID: 2126347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time course of bromocriptine induced excitation in the rat: behavioural and biochemical studies.
    Jackson DM; Mohell N; Georgiev J; Bengtsson A; Larsson LG; Magnusson O; Ross SB
    Naunyn Schmiedebergs Arch Pharmacol; 1995 Feb; 351(2):146-55. PubMed ID: 7539523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral evidence for supersensitivity after chronic bromocriptine administration.
    Smith RC; Strong JR; Hicks PB; Samorajski T
    Psychopharmacology (Berl); 1979 Feb; 60(3):241-6. PubMed ID: 108701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic L-dopa treatment of rats and mice does not change the sensitivity of post-synaptic dopamine receptors.
    Jackson DM; Jenkins OF; Malor R; Christie MJ; Gregory P
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Dec; 324(4):271-4. PubMed ID: 6686648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postsynaptic dopamine/adenosine interaction: I. Adenosine analogues inhibit dopamine D2-mediated behaviour in short-term reserpinized mice.
    Ferré S; Herrera-Marschitz M; Grabowska-Andén M; Ungerstedt U; Casas M; Andén NE
    Eur J Pharmacol; 1991 Jan; 192(1):25-30. PubMed ID: 1828236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different roles of D-1 and D-2 dopamine receptors involved in locomotor activity of supersensitive mice.
    Rubinstein M; Gershanik O; Stefano FJ
    Eur J Pharmacol; 1988 Apr; 148(3):419-26. PubMed ID: 2968273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why does clozapine stimulate the motor activity of reserpine-pretreated rats when combined with a dopamine D1 receptor agonist?
    Jackson DM; Mohell N; Bengtsson A; Malmberg A
    Eur J Pharmacol; 1995 Aug; 282(1-3):137-44. PubMed ID: 7498268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.